Evaluation of G3BP1 in the prognosis of acute and acute-on-chronic liver failure after the treatment of artificial liver support system

Table 2 Multivariable Cox regression analyses of difference of G3BP1 between the level of discharge and admission discharge and admission for predicting the risk for progression in training cohort

	G3BP1 cut points	Progression (%)1	Unadjusted HR (95%CI)	P value	Model 13	Adjusted HR (95%CI) P value
Total cohort (n = 244)
T1 + T2 G3BP1 (n = 161)	≥ 0	14 (8.7)	1.0 (Reference)		1.0 (Reference)
T3 G3BP1 (n = 83)	< 0	64 (77.1)	11.70 (6.50-21.04)	< 0.001	9.23 (5.08-16.75)	< 0.001
Subgroup with MELD2 high risk (n = 154)
T2 + T3 G3BP1 (n = 94)	≥ 0	13 (13.8)	1.0 (Reference)		1.0 (Reference)
T1 G3BP1 (n = 60)	< 0	53 (88.3)	8.01 (4.33-14.81)	< 0.001	5.71 (3.04-10.74)	< 0.001
Subgroup with MELD low-medium risk (n = 90)
T2 + T3 G3BP1 (n = 67)	≥ 0	1 (1.5)	1.0 (Reference)		1.0 (Reference)
T1 G3BP1 (n = 23)	< 0	11 (47.8)	39.46 (5.05-308.3)	< 0.001	23.80 (2.96-191.3)	< 0.001

¹The progression was death or liver transplantation.

²Model for end-stage liver disease score = 3.78 × ln [total bilirubin (μmol/L)/17.1] + 11.2 × ln (international normalized ratio) + 9.57 × ln [creatinine (μmol/L)/88.4] + 6.43. The higher the score, the worse the prognosis. The score of low risk is ≤ 14 points, the score of medium risk is 15-18 points, and the score of high risk is > 18 points.

³Model 1 adjusts the linear variables lactate dehydrogenase, alpha-fetoprotein.

HR: Hazard ratio; MELD: Model for end-stage liver disease.